Veracyte

Q2 FY2026 EarningsQ2 FY26 results beat consensus estimates across top and bottom lines: revenue reached $150.3M (+4.0% vs. $144.5M expected) and diluted EPS was $0.31 (+19.2% vs. $0.26 mean). The performance was driven by a 19% YoY surge in testing revenue, bolstered by a 14% volume increase and $4.5M in favorable prior-period cash collections. While gross margin of 72.2% slightly missed the 73.2% target due to infrastructure scaling, EBIT of $23.0M significantly exceeded the $19.7M consensus, reflecting improved operating leverage despite a major reclassification of software expenses from G&A to R&D.